Novogenia AG (ticker symbol: 7V0), a Munich-based healthcare company focused on human genetics, announced it will serve as the exclusive technology and manufacturing partner in a planned clinical study under the 10XREVIV initiative in Abu Dhabi, United Arab Emirates. The study, involving healthcare partners M42, 10X Health, and REVIV Global, will examine whether personalized dietary supplements can improve the nutritional status, body composition, well-being, and treatment adherence of patients receiving GLP-1 therapy. The announcement, distributed via NEWMEDIAWIRE, signals a significant step in applying genetic insights to mainstream chronic care.
The study design initially calls for 500 participants in Abu Dhabi. Novogenia will conduct and evaluate participants’ DNA analyses, then develop and manufacture individually tailored dietary supplements based on those results. The trial, led by Insights Research Organization and Solutions (IROS), a contract research organization belonging to M42, and 10XREVIV, will assess how tailored nutritional support alongside standard care affects nutritional status, muscle and fat percentages, quality of life, fatigue levels, and consistent adherence to treatment.
Why this matters: GLP-1-based medications are transforming weight management, but they carry nutritional risks. A U.S. study published in 2025 involving more than 460,000 adults prescribed GLP-1 therapy found that 22.4% experienced a nutrient deficiency or related complication for the first time within one year. As GLP-1 therapies become more widely used, ensuring adequate nutrient intake is gaining importance. The global market for GLP-1 receptor agonists is expected to rise from approximately $66 billion in 2025 to more than $185 billion by 2033, according to market forecasts. Novogenia’s involvement positions it at the intersection of two fast-growing fields—personalized nutrition and GLP-1 therapy—potentially creating a new standard of care that pairs genetic analysis with supplementation.
“The 10XREVIV initiative is a key component of our international growth strategy,” said Dr. Daniel Wallerstorfer, CEO of Novogenia AG. “Through our participation in the planned study, we are contributing our core competencies in genetic analysis and the manufacture of personalized dietary supplements to a scientific study. The study aims to provide insights into the additional benefits that individually tailored nutritional support can offer to people receiving GLP-1 therapy.”
The initiative also advances Novogenia’s international expansion. The company has adapted its products to regional requirements in the Middle East, including obtaining Halal certification. The operational launch of 10XREVIV coincides with strong growth in GLP-1 therapies, creating new opportunities for Novogenia to apply its expertise in genetic analysis and personalized supplement manufacturing to innovative care models. By participating in the planned study, Novogenia strengthens its position as a technology and manufacturing partner in personalized healthcare and builds on its previously communicated strategic direction. For more details, see the original release.


